Alector Investigated for Potential Securities Law Violations Over Misleading Statements.
ByAinvest
Wednesday, Nov 19, 2025 9:56 am ET1min read
ALEC--
Alector, Inc. is under investigation for alleged securities law violations related to its Phase 3 INFRONT-3 clinical trial for latozinemab (AL001) in frontotemporal dementia due to a progranulin gene mutation. The drug candidate failed to meet clinical co-primary endpoints and did not demonstrate treatment-related effects on secondary and exploratory endpoints. This news led to a decline in shares.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet